Mexico Antifungal Drugs Market Size & Outlook, 2023-2030
Mexico antifungal drugs market, 2018-2030 (US$M)
Related Markets
Mexico antifungal drugs market highlights
- The Mexico antifungal drugs market generated a revenue of USD 143.0 million in 2023 and is expected to reach USD 200.0 million by 2030.
- The Mexico market is expected to grow at a CAGR of 4.9% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 143.0 million |
| Market revenue in 2030 | USD 200.0 million |
| Growth rate | 4.9% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.9% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 262.6 million by 2030.
Azoles was the largest segment with a revenue share of 48.81% in 2023. Horizon Databook has segmented the Mexico antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
The Federal Commission for Protection against Sanitary Risks (COFEPRIS) is a health authority agency that regulates drugs and medical devices in Mexico and operates under the Mexican Ministry of Health.
Biologics and combination products need authorization and approval from COFEPRIS. The pharmaceutical products are approved under the General Health Law (Ley General de Salud) supplemented by Guidelines and Official Norms (NOMS).
The approval time can vary from 180 to 240 days depending on the drug. For the approval of generics, data regarding bioavailability of the drug has to be provided.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico antifungal drugs market size, by drug class, 2018-2030 (US$M)
Mexico Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
